Incyte Q2 Beat; raises 2026 sales guidance but misses consensus
Jul 29, 2026, 11:12 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Beat on earnings despite lower-than-expected full-year guidance relative to consensus caused a modest stock pullback; historical pattern shows INCY reactions hinge on how guidance compares to street expectations and pipeline visibility.
AI summary
What happened, with direct paths to the underlying reporting
Incyte topped Q2 expectations with adjusted EPS of $3.09 and revenue of $1.67B, up 38% year over year. The company lifted 2026 net sales guidance to $5.13–5.26B, but the range remains below consensus of about $5.71B, triggering a modest after-hours stock move. The result highlights solid pipeline progress and strategic momentum, tempered by valuation and guidance risk versus peers.
Q2 adj EPS $3.09 vs $2.12 est; revenue $1.67B, +38% YoY.
Guidance: 2026 net sales raised to $5.13-5.26B, below consensus $5.712B.
Stock down 1.7% to $127.75 after earnings.
Analysts updated price targets post-earnings.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Incyte reported stronger Q2 earnings and raised its full-year revenue forecast after settling a U.S. government Medicaid rebates lawsuit linked to Opzelura. The settlement reduces…
Incyte reported that Monjuvi, when added to a chemotherapy standard of care, cut the relative risk of progression, relapse, or death by 25% in an aggressive non-Hodgkin lymphoma t…
Incyte has announced a substantial $120 million partnership with Genesis Molecular AI, which includes $80 million upfront and $40 million in equity. This collaboration aims to lev…
Incyte reported better-than-expected Q1 earnings, primarily driven by robust sales of its cancer therapies, Jakafi and Minjuvi. This performance suggests a strong growth trajector…